Bristol-Myers Squibb Co. talked up its commitment to the CTLA-4 checkpoint target, accentuating its strong qualities and track record, while also saying it is "not wedded" to the CTLA-4/PD-1 combination in lung cancer and has lots of options, during its second-quarter earnings call July 27.
Post-MYSTIC, Bristol Renews CTLA-4 Vows, But Is "Not Wedded" In Lung Cancer
Company distances its CheckMate 227 CTLA-4/PD-1 combo study from AstraZeneca's doomed MYSTIC trial, noting big differences, but also makes it clear that its options are very open for monotherapy and chemo combos in first-line lung cancer.
More from R&D
More from Scrip
• By
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.